Aline Vandenbulcke

Kortrijk, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

A novel p.C1130S mutation in a Finnish family with a complex phenotype of von Willebrand disease.

A novel p.C1130S mutation in a Finnish family with a complex phenotype of von Willebrand disease.

Journal: Haematologica

Published: May 07, 2025

Association Between Thrombus Composition and Etiology in Patients With Acute Ischemic Stroke Treated by Thrombectomy.

Association Between Thrombus Composition and Etiology in Patients With Acute Ischemic Stroke Treated by Thrombectomy.

Journal: Stroke

Published: March 24, 2025

Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity.

Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity.

Journal: International journal of molecular sciences

Published: March 24, 2023

ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation.

ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 23, 2022

High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.

High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.

Journal: Viruses

Published: May 10, 2022

Improvement of recombinant ADAMTS13 production through a more optimal signal peptide or an N-terminal fusion protein.

Improvement of recombinant ADAMTS13 production through a more optimal signal peptide or an N-terminal fusion protein.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 22, 2022

Determination of anti-ADAMTS-13 autoantibody titers in ELISA: Influence of ADAMTS-13 presentation and autoantibody detection.

Determination of anti-ADAMTS-13 autoantibody titers in ELISA: Influence of ADAMTS-13 presentation and autoantibody detection.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 06, 2021

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.

Journal: Blood

Published: November 20, 2019

The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice.

The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice.

Journal: Haematologica

Published: October 18, 2019

Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.

Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.

Journal: Journal of thrombosis and haemostasis : JTH

Published: September 10, 2019

Crystal structure and substrate-induced activation of ADAMTS13.

Crystal structure and substrate-induced activation of ADAMTS13.

Journal: Nature communications

Published: March 08, 2019

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Journal: Thrombosis and haemostasis

Published: September 21, 2018

Showing 1-12 of 21

Last Updated: 09/26/2026